Chronic Liraglutide Administration Fails to Suppress Postprandial Glucagon Levels in Type 1 Diabetic Islet Allograft Recipients With Graft Dysfunction

Transplantation. 2018 Jan;102(1):e39-e40. doi: 10.1097/TP.0000000000001964.

Authors

Francesco Vendrame^{1

2}, Nathalia Padilla¹, Eduardo Peixoto^{1

3}, David Baidal^{1

2}, Violet Lagari^{1

2}, Ana Alvarez Gil¹, Alejandro Mantero⁴, Shari Messinger⁴, Camillo Ricordi¹, Rodolfo Alejandro^{1

2}

Affiliations

¹ Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL.
² Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
³ Department of Internal Medicine, Framingham Union Hospital, Metrowest Medical Center, Boston, MA.
⁴ Department of Public Health Sciences, University of Miami, Miami FL.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 1 / blood
Diabetes Mellitus, Type 1 / therapy*
Glucagon / blood*
Humans
Hypoglycemic Agents / adverse effects*
Islets of Langerhans Transplantation*
Liraglutide / adverse effects*
Postprandial Period*

Substances

Hypoglycemic Agents
Liraglutide
Glucagon

Grants and funding